harriet brown

A recently FDA-approved weight loss drug heralded as “game-changing” by some researchers is selling like hotcakes. On Wednesday, Novo Nordisk announced an unexpectedly strong third quarter, fuelled by the release of its obesity drug Wegovy in the U.S. earlier this summer. The drug’s popularity has made it hard to get for some prospective patients, however,…